Hyaluronic Acid and Free Gingival Graft Healing

Sponsor
University of Zagreb (Other)
Overall Status
Recruiting
CT.gov ID
NCT05990049
Collaborator
(none)
40
1
2
12
3.3

Study Details

Study Description

Brief Summary

This study aims to evaluate the impact of locally applied hyaluronic acid on free gingival graft wound bed healing and palatal donor site wound healing.

Forty subjects will be randomly divided in two separate groups. Test group will be treated with hyaluronic acid during the procedure and the control group without.

Periodontal parameters and other clinical measurements will be taken on baseline, 7 days postoperative, 14 days postoperative, 1 month, 3 months and 6 months postoperative.

Condition or Disease Intervention/Treatment Phase
  • Drug: Hyadent BG
Phase 3

Detailed Description

Free gingival graft is common, simple and predictable surgical procedure. Patients who have keratinized tissue width less than 2 mm will undergo the surgery after passing the inclusion criteria together with initial periodontal therapy. Total number of 40 patients will be divided in two separate groups; test group (hyaluronic acid) and control group based on random choice.The randomization will be examiner blind.

After the application of local anaesthesia, surgical procedure will be done in the same groups equally. In the recipient site, an horizontal incision will be performed on the mucogingival junction or 1-2 mm above it to include the free marginal gingiva. Partial thickness flap will be dissected in order to ensure the vascularisation of the graft. The size of the incision and graft will depend on the keratinized tissue width of the teeth area.

The graft will be taken from the donor site on the anterior palate in the area of premolars and molars. The graft will be measured with periodontal probe (UNC-15) in 3 dimensions over the flat surface and after the harvesting will be put in glass with saline. Donor site will be sutured using fibrin sponge and non-resorbable sutures. The size of recipient site and graft will depend on number of teeth with keratinized tissue width less than 2 mm.

The graft will be positioned on the recipient site and stabilised using non-resorbable suture performing single sutures and a sling suture around the tooth. The group of patients who will receive the hyaluronic acid will be treated on donor and recipient site before the suturing, applied once on the wound bed.

Postoperatively, patients will be instructed to rinse with 0.12% chlorhexidine digluconate twice a day. The patients will be asked to keep a diary for 7 days about pain sensations using VAS scale for donor and recipient site. An analgetic treatment will be prescribed if needed.

Recall visits will be 7 and 14 days postoperatively. The 7th day postoperatively will be removed sutures from donor site, and on 14th day the sutures from the graft and recipient site.

Clinical measurements with periodontal indices will be taken on 1, 3, and 6 months follow up.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
40 participants
Allocation:
Randomized
Intervention Model:
Parallel Assignment
Masking:
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose:
Treatment
Official Title:
Impact of Hyaluronic Acid on Free Gingival Graft Healing and Palatal Donor Site Wound Healing
Actual Study Start Date :
Mar 1, 2023
Anticipated Primary Completion Date :
Jan 1, 2024
Anticipated Study Completion Date :
Mar 1, 2024

Arms and Interventions

Arm Intervention/Treatment
Active Comparator: Hyaluronic acid

During the surgery, the hyaluronic acid will be administered on donor site wound and on recipient site before suturing.

Drug: Hyadent BG
Hyadent BG is a cross-linked hyaluronic acid. 1,6% cross-linked hyaluronic acid (xHA), 0,2% native hyaluronic acid (HA)

No Intervention: Control

After the harvesting of the graft from the donor site, the wound will be sutured using only saline to clean the wound. On the recipient site, before positioning the graft, only saline will be used.

Outcome Measures

Primary Outcome Measures

  1. Keratinized tissue gain [baseline to 1 month postoperatively]

    changes of the tissue in apico - coronal dimensions from gingival margin to mucogingival junction

  2. Keratinized tissue gain [baseline to 3 months postoperatively]

    changes of the tissue in apico - coronal dimensions from gingival margin to mucogingival junction

  3. Keratinized tissue gain [baseline to 6 months postoperatively]

    changes of the tissue in apico - coronal dimensions from gingival margin to mucogingival junction

  4. Shrinkage of the graft [baseline to 1 month postoperatively]

    changes of the graft in apico - coronal and mesio-distal dimensions

  5. Shrinkage of the graft [baseline to 3 months postoperatively]

    changes of the graft in apico - coronal and mesio-distal dimensions

  6. Shrinkage of the graft [baseline to 6 months postoperatively]

    changes of the graft in apico - coronal and mesio-distal dimensions

Secondary Outcome Measures

  1. Dimensional changes in gingival recessions [baseline to 1 month postoperative]

    reduction of gingival recessions

  2. Dimensional changes in gingival recessions [baseline to 3 months postoperative]

    reduction of gingival recessions

  3. Dimensional changes in gingival recessions [baseline to 6 months postoperative]

    reduction of gingival recessions

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 70 Years
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • no systemic disease

  • healthy

  • non-smokers

  • at least one tooth with keratinized tissue width less than 2 mm

Exclusion Criteria:
  • heavy smokers

  • younger than 18years old

  • using drugs

  • allergy on anesthesia

  • using drugs or alcohol

  • undergoing chemotherapy

  • undergoing radiotherapy

Contacts and Locations

Locations

Site City State Country Postal Code
1 School of Dental Medicine University of Zagreb Zagreb Croatia 10000

Sponsors and Collaborators

  • University of Zagreb

Investigators

  • Study Director: Ana Badovinac, assoc prof, School of Dental Medicine University of Zagreb

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Ana Badovinac, assistant professor, University of Zagreb
ClinicalTrials.gov Identifier:
NCT05990049
Other Study ID Numbers:
  • 05-PA-30-V-2/2022.
First Posted:
Aug 14, 2023
Last Update Posted:
Aug 16, 2023
Last Verified:
Aug 1, 2023
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Ana Badovinac, assistant professor, University of Zagreb
Additional relevant MeSH terms:

Study Results

No Results Posted as of Aug 16, 2023